Day: July 19, 2019

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

MarketsandMarkets Conferences
AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been disclosed yet. AveXis will use the dedicated production space within Paragon’s Harmans, MD, facility, a 151,000-square-foot old warehouse that Paragon changed into a contract developing and a manufacturing site which opened in April. Andy Stober,…

Read More

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

MarketsandMarkets Conferences
Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…

Read More